Exact Mass: 676.0753625999998
Exact Mass Matches: 676.0753625999998
Found 18 metabolites which its exact mass value is equals to given mass value 676.0753625999998,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
5-O-phosphonoadenylyl-(3->5)-adenosine
C20H26N10O13P2 (676.1156006000001)
Diadenosine diphosphate
C20H26N10O13P2 (676.1156006000001)
Diadenosine diphosphate is a member of the diadenosine polyphosphates. Diadenosine diphosphate is typically synthesized from ADP-ribosyl cyclases. Diadenosine polyphosphates are members of a group of dinucleoside polyphosphates that are ubiquitous, naturally occurring molecules. They form a recently identified class of compounds derived from ATP and consist of two adenosine molecules bridged by up to six phosphate groups. These compounds are stored in high concentrations in platelet dense granules and are released when platelets become activated. Some of the compounds promote platelet aggregation, while others are inhibitory. Possible roles as neurotransmitters, extracellular signalling molecules or alarmones secreted by cells in response to physiologically stressful stimuli have been postulated. Recent studies suggest a role for these compounds in atrial and synaptic neurotransmission. Studies using isolated mesenteric arteries indicate an important role of phosphate chain length in determining whether diadenosine polyphosphates produce vasodilatation or vasoconstriction, but in the coronary circulation, diadenosine polyphosphates generally produce vasodilatation via mechanisms thought to involve release of NO or prostacyclin (PGI2). They produce cardiac electrophysiological effects by altering ventricular refractoriness at submicromolar concentrations and reduce heart rate. Mechanisms involving KATP channels have been proposed in addition to the involvement of P1- and P2-purinergic receptors and the specific diadenosine polyphosphate receptor identified on isolated cardiac myocytes. Clinical evidence suggests a role for diadenosine polyphosphates in hypertensive patients and those with the Chediak-Higashi syndrome. (PMID: 10434992) [HMDB] Diadenosine diphosphate is a member of the diadenosine polyphosphates. Diadenosine diphosphate is typically synthesized from ADP-ribosyl cyclases. Diadenosine polyphosphates are members of a group of dinucleoside polyphosphates that are ubiquitous, naturally occurring molecules. They form a recently identified class of compounds derived from ATP and consist of two adenosine molecules bridged by up to six phosphate groups. These compounds are stored in high concentrations in platelet dense granules and are released when platelets become activated. Some of the compounds promote platelet aggregation, while others are inhibitory. Possible roles as neurotransmitters, extracellular signalling molecules or alarmones secreted by cells in response to physiologically stressful stimuli have been postulated. Recent studies suggest a role for these compounds in atrial and synaptic neurotransmission. Studies using isolated mesenteric arteries indicate an important role of phosphate chain length in determining whether diadenosine polyphosphates produce vasodilatation or vasoconstriction, but in the coronary circulation, diadenosine polyphosphates generally produce vasodilatation via mechanisms thought to involve release of NO or prostacyclin (PGI2). They produce cardiac electrophysiological effects by altering ventricular refractoriness at submicromolar concentrations and reduce heart rate. Mechanisms involving KATP channels have been proposed in addition to the involvement of P1- and P2-purinergic receptors and the specific diadenosine polyphosphate receptor identified on isolated cardiac myocytes. Clinical evidence suggests a role for diadenosine polyphosphates in hypertensive patients and those with the Chediak-Higashi syndrome. (PMID: 10434992).
Adenylyl-(5-2)-5-adenylsaeure|D,D-pA(2-5)pA|p5A2p5A|pA2p5A|pA2pA
C20H26N10O13P2 (676.1156006000001)
3-(CARBETHOXY)-3-(METHYLCARBETHOXY)-5-(1H,1H-PERFLUORONONYL)--BUTYROLACTONE
C20H17F17O6 (676.0753625999998)
disodium 2-[4-[[1-[[(2-methoxy-5-methyl-4-sulphonatophenyl)amino]carbonyl]-2-oxopropyl]azo]phenyl]-6-methylbenzothiazole-7-sulphonate
1,3-Naphthalenedisulfonicacid,8-[2-[4-[2-(4-ethoxyphenyl)diazenyl][1,1-biphenyl]-4-yl]diazenyl]-7-hydroxy-,sodium salt (1:2)
C30H22N4Na2O8S2 (676.0674412000001)
Deoxydiguanosine diphosphosphate
C20H26N10O13P2 (676.1156006000001)
[6-[5,7-Dihydroxy-4-oxo-8-(3,4,5-trihydroxyoxan-2-yl)-2-(2,4,5-trihydroxyphenyl)chromen-6-yl]-3,4,5-trihydroxyoxan-2-yl]methyl hydrogen sulate
C26H28O19S (676.0945458000001)
PAPA
C20H26N10O13P2 (676.1156006000001)
A 5-phospho-(3->5)-dinucleotide composed from two AMP residues.
5-d(pGpG)-3
C20H26N10O13P2 (676.1156006000001)
A single-stranded DNA oligonucleotide comprising two 2-deoxyguanosine residues connected by a 3->5 linkage and with a phosphoric group at the 5-terminus.